PO.TB10.18 · 肿瘤生物学
通过新型PNA导向qPCR检测量化消化系统癌症中TCF-4变体的表达谱
Expression profiles of TCF-4 variants across digestive system cancers quantified by a novel PNA-directed qPCR assay
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:TCF-4是Wnt/beta-catenin通路中的一个关键转录因子,可产生具有不同功能的多种剪接变体。尽管我们团队此前在肝癌细胞中鉴定出14种变体,但由于传统检测方法分辨率低,跨消化系统癌症的定量评估一直受限。为解决这一未满足的需求,我们开发了一种基于肽核酸(PNA)导向PCR钳制的定量RT-PCR系统,能够精确区分单个TCF-4剪接变体。
目的:建立一个稳健的定量框架,用于变体水平的TCF-4表达分析,并描绘消化系统癌症细胞系和结直肠癌(CRC)组织中器官特异性的表达模式,重点关注功能上不同的变体TCF-4J(SxxSS−)和TCF-4K(SxxSS+)。方法:构建了一个PNA-qPCR平台,用于灵敏区分密切相关的TCF-4剪接变体。分析了代表肝、胃、结直肠、胰腺和胰腺神经内分泌肿瘤的16个细胞系。在39对配对的CRC组织及相邻黏膜(经IRB批准)中进一步量化了TCF-4J和TCF-4K的表达水平。使用基于四分位数的肿瘤TCF-4J表达分层进行了探索性亚组分析。
结果:PNA-qPCR系统实现了对14种TCF-4变体的特异性定量。观察到明显的器官依赖性表达特征:肝癌细胞系显示出以TCF-4B为主的模式,而胃癌、结直肠癌和胰腺癌细胞系表现出以TCF-4J为主的谱型,表明变体的使用是谱系特异性的,而非依赖分化的变化。在CRC组织中,TCF-4J相对于非癌黏膜显著上调,而TCF-4K表达保持较低。探索性四分位数分析揭示,肿瘤TCF-4J表达处于最低25%的患者无远处转移,且该亚组相比高表达病例显示出总生存期延长的趋势(51个月对23个月)。
结论:本研究建立了一个用于TCF-4变体分析的灵敏定量平台,并揭示了消化系统恶性肿瘤中变体使用的显著器官特异性差异。CRC中低TCF-4J表达与转移进展之间的负相关关系提示潜在的生物学相关性。将这一基于批量RNA的框架与单细胞和空间转录组学方法整合,对于阐明变体特异性调控和肿瘤内异质性将至关重要。
查看英文原文 English abstract
Background: TCF-4, a key transcription factor in the Wnt/beta-catenin pathway, produces multiple splice variants with distinct functions. Although our group previously identified 14 variants in liver cancer cells, quantitative assessment across digestive system cancers has been limited by the low resolution of conventional assays. To address this unmet need, we developed a peptide nucleic acid (PNA)-directed PCR clamping-based quantitative RT-PCR system enabling precise discrimination of individual TCF-4 splice variants.
Purpose: To establish a robust quantitative framework for variant-level TCF-4 expression analysis and delineate organ-specific expression patterns across digestive cancer cell lines and colorectal cancer (CRC) tissues, with emphasis on the functionally distinct variants TCF-4J (SxxSS−) and TCF-4K (SxxSS+). Methods: A PNA-qPCR platform was constructed for sensitive discrimination of closely related TCF-4 splice variants. Sixteen cell lines representing liver, stomach, colorectum, pancreas, and pancreatic neuroendocrine tumors were analyzed. TCF-4J and TCF-4K expression levels were further quantified in 39 paired CRC tissues and adjacent mucosa (IRB-approved). An exploratory subgroup analysis was performed using quartile-based stratification of tumor TCF-4J expression.
Results: The PNA-qPCR system enabled specific quantification of 14 TCF-4 variants. Distinct organ-dependent expression signatures were observed: liver cancer cell lines showed a predominantly TCF-4B-dominant pattern, whereas gastric, colorectal, and pancreatic cancer lines exhibited TCF-4J-dominant profiles, indicating lineage-specific variant usage rather than differentiation-dependent changes. In CRC tissues, TCF-4J was significantly upregulated relative to noncancerous mucosa, whereas TCF-4K expression remained low. Exploratory quartile analysis revealed that patients in the lowest 25% of tumor TCF-4J expression had no distant metastasis, and this subgroup showed a trend toward longer overall survival compared with higher-expression cases (51 vs. 23 months).
Conclusions: This study establishes a sensitive quantitative platform for TCF-4 variant profiling and reveals striking organ-specific differences in variant usage across digestive system malignancies. The inverse relationship between low TCF-4J expression and metastatic progression in CRC suggests potential biological relevance. Integration of this bulk RNA-based framework with single-cell and spatial transcriptomic approaches will be essential to elucidate variant-specific regulation and intratumoral heterogeneity.
利益披露 Disclosure
H. Koga, None..
Y. Imamura, None..
T. Sudo, None.